| Michael Tyler King, MD | |
|
3600 W Bethel Ave, Muncie, IN 47304-5407 | |
| (800) 622-6575 | |
| Not Available |
| Full Name | Michael Tyler King |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 12 Years |
| Location | 3600 W Bethel Ave, Muncie, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306112669 | NPI | - | NPPES |
| 264430B51 | Other | IN | MEDICARE PTAN |
| 201386470 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | A126418 (California) | Secondary |
| 207L00000X | Anesthesiology | 01077058A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Indiana Orthopedics Llc | 5698667822 | 142 |
| Indiana University Health Care Associates Inc | 5799755864 | 882 |
News Archive
Few events strike more fear in parents than hearing their child's heart "hurts."
An academic team which includes key researchers from the Universities of Manchester and Hull has taken both first and second prizes, in a nationwide innovation competition run by Microsoft.
In a presentation at the Conference on Lasers and Electro-Optics (CLEO), researchers from Cedars-Sinai Medical Center's Biophotonics Research and Technology Development Laboratory described recent progress on a device that stimulates, collects and measures light emissions from body tissues to diagnose critical atherosclerotic plaques (vulnerable plaques) and aggressive brain tumors.
Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.
› Verified 9 days ago
| Entity Name | Central Indiana Orthopedics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063422137 PECOS PAC ID: 5698667822 Enrollment ID: O20040325000156 |
News Archive
Few events strike more fear in parents than hearing their child's heart "hurts."
An academic team which includes key researchers from the Universities of Manchester and Hull has taken both first and second prizes, in a nationwide innovation competition run by Microsoft.
In a presentation at the Conference on Lasers and Electro-Optics (CLEO), researchers from Cedars-Sinai Medical Center's Biophotonics Research and Technology Development Laboratory described recent progress on a device that stimulates, collects and measures light emissions from body tissues to diagnose critical atherosclerotic plaques (vulnerable plaques) and aggressive brain tumors.
Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.
› Verified 9 days ago
| Entity Name | Iu Anesthesiology Associates, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285684407 PECOS PAC ID: 5395730303 Enrollment ID: O20040419001228 |
News Archive
Few events strike more fear in parents than hearing their child's heart "hurts."
An academic team which includes key researchers from the Universities of Manchester and Hull has taken both first and second prizes, in a nationwide innovation competition run by Microsoft.
In a presentation at the Conference on Lasers and Electro-Optics (CLEO), researchers from Cedars-Sinai Medical Center's Biophotonics Research and Technology Development Laboratory described recent progress on a device that stimulates, collects and measures light emissions from body tissues to diagnose critical atherosclerotic plaques (vulnerable plaques) and aggressive brain tumors.
Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.
› Verified 9 days ago
| Entity Name | Indiana University Health Care Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902032832 PECOS PAC ID: 5799755864 Enrollment ID: O20040727000955 |
News Archive
Few events strike more fear in parents than hearing their child's heart "hurts."
An academic team which includes key researchers from the Universities of Manchester and Hull has taken both first and second prizes, in a nationwide innovation competition run by Microsoft.
In a presentation at the Conference on Lasers and Electro-Optics (CLEO), researchers from Cedars-Sinai Medical Center's Biophotonics Research and Technology Development Laboratory described recent progress on a device that stimulates, collects and measures light emissions from body tissues to diagnose critical atherosclerotic plaques (vulnerable plaques) and aggressive brain tumors.
Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.
› Verified 9 days ago
| Entity Name | Aas Indiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831827021 PECOS PAC ID: 4688045115 Enrollment ID: O20230120001025 |
News Archive
Few events strike more fear in parents than hearing their child's heart "hurts."
An academic team which includes key researchers from the Universities of Manchester and Hull has taken both first and second prizes, in a nationwide innovation competition run by Microsoft.
In a presentation at the Conference on Lasers and Electro-Optics (CLEO), researchers from Cedars-Sinai Medical Center's Biophotonics Research and Technology Development Laboratory described recent progress on a device that stimulates, collects and measures light emissions from body tissues to diagnose critical atherosclerotic plaques (vulnerable plaques) and aggressive brain tumors.
Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Tyler King, MD 3600 W Bethel Ave, Muncie, IN 47304-5407 Ph: (800) 622-6575 | Michael Tyler King, MD 3600 W Bethel Ave, Muncie, IN 47304-5407 Ph: (800) 622-6575 |
News Archive
Few events strike more fear in parents than hearing their child's heart "hurts."
An academic team which includes key researchers from the Universities of Manchester and Hull has taken both first and second prizes, in a nationwide innovation competition run by Microsoft.
In a presentation at the Conference on Lasers and Electro-Optics (CLEO), researchers from Cedars-Sinai Medical Center's Biophotonics Research and Technology Development Laboratory described recent progress on a device that stimulates, collects and measures light emissions from body tissues to diagnose critical atherosclerotic plaques (vulnerable plaques) and aggressive brain tumors.
Gilead Sciences, Inc. today announced that the second pivotal Phase 3 clinical trial of its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate, being evaluated for HIV-1 infection in treatment-naïve patients, met its primary objective of non-inferiority at week 48 as compared to ritonavir-boosted atazanavir plus Truvada.
› Verified 9 days ago
Leah Bryant Jamison, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-751-2649 Fax: 765-281-6671 | |
Vikas Raghove, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-747-3111 | |
Gregory S Eskew, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2401 University Ave, Muncie, IN 47303 Phone: 765-741-3111 Fax: 765-741-1877 | |
Dr. Steve Pierre, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-751-2649 Fax: 765-281-6671 | |
Gregory J Allred, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-751-5404 Fax: 765-751-2757 | |
Dr. Michael Norman Allen, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 2401 W University Ave, Muncie, IN 47303 Phone: 765-747-3111 | |
Robert M Dove, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2401 University Ave, Muncie, IN 47303 Phone: 765-741-3111 Fax: 765-741-1877 |